ST人福：HW221043片临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HW221043 tablets in patients with advanced solid tumors, marking a significant step in its drug development efforts [1] Group 1: Drug Development - HW221043 tablets are intended for the treatment of advanced solid tumors and are a new molecular entity developed by the company [1] - Currently, there are no similar drugs approved for market in both domestic and international markets [1] - The total research and development investment for HW221043 tablets has reached approximately 24 million RMB [1]